Invest-NL Injects €15 Million to Bridge the Healthcare Technology Funding Gap
Amsterdam, Monday 16 March 2026
In March 2026, Invest-NL committed €15 million to bridge a critical funding gap, empowering healthtech companies to rapidly scale vital medical and digital healthcare solutions across the Benelux region.
Addressing the Series A and B Bottleneck
Despite rapid initial growth, numerous medical technology and digital health enterprises frequently encounter substantial hurdles when attempting to secure growth capital [1]. Within the Netherlands and the broader European market, there is a pronounced scarcity of funding available during the critical Series A and B investment phases [1]. This financial bottleneck actively impedes the commercial scaling of vital innovations, particularly those aimed at enhancing diagnostics, advancing digital monitoring, and introducing novel medical technologies [1]. Ultimately, these are the very solutions required to simultaneously improve patient outcomes and reduce overarching systemic healthcare costs [1].
Mobilising International Private Equity
The highly specialised focus and specific scale of the HE3 fund inherently appeal to a different investor demographic than EQT’s traditional private equity offerings [1]. Invest-NL’s cornerstone capital injection was pivotal in elevating the fund’s total volume to a threshold deemed attractive by international institutional investors [1]. Consequently, this foundational support has proven successful in mobilising crucial additional capital for this specialised market segment [1].
Sustainable Healthcare Through Strategic Investment
Ultimately, the strategic allocation of funds into Health Economics 3 serves a dual purpose: accelerating domestic enterprise growth and safeguarding the future of the healthcare system [1]. By facilitating the development and subsequent scaling of advanced medical innovations, Invest-NL directly contributes to a framework where healthcare remains affordable, practically executable, and universally accessible [1]. This objective remains a central pillar of Invest-NL’s overarching investment philosophy within the life sciences domain [1].